GRAIL, Inc. (GRAL) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in Menlo Park, CA, United States. The current CEO is Robert Ragusa.
GRAL has IPO date of 2024-06-12, 1,000 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.07B.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
